Porovnať metódy

	Rýchle hodnotenie údajov o pacientovi 3 (RAPID3)	Skóre aktivity choroby 28 kĺbov (DAS28)	Index aktivity ochorenia systémového lupus erythematosus 2000 (SLEDAI-2K)
Odbor	Reumatológia	Reumatológia	Reumatológia
Rodina	Process / pipeline	Process / pipeline	Process / pipeline
Rok vzniku	2008	1995	2002
Tvorca	Pincus et al.	Prevoo et al.	Gladman et al.
Typ	Patient-reported outcome (PRO)	Clinician-rated	Clinician-rated
Pôvodný zdroj	Pincus T, Bergman MJ, Sokka T, Roth SH, Swearingen C, Yazici Y. Activity of rheumatoid arthritis is similar in patients seen in a primary care physician-based practice and in an academic rheumatology-based practice. Arthritis Care Research. 2008;59(9):1229-1236.	Prevoo ML, Hart's AM, Van Houwelingen HC, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis & Rheumatism. 1995;38(1):44-48.	Gladman DD, Ibañez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. The Journal of Rheumatology. 2002;29(2):288-291.
Ďalšie názvy	RAPID3, RAPID-3	DAS28, DAS28-CRP, DAS28-ESR	SLEDAI, SLEDAI-2K, SLE Disease Activity Index
Príbuzné	3	3	3
Zhrnutie	RAPID3 is a patient-reported outcome (PRO) measure of rheumatoid arthritis disease activity based on three simple self-report items: patient-counted swollen and tender joints and overall health assessment. Introduced by Pincus et al. in 2008, RAPID3 was designed for primary care and busy practices where joint examination is impractical or time-limited. Remarkably, RAPID3 correlates strongly with clinician-examined composite measures (DAS28, CDAI, SDAI) and predicts long-term radiographic progression equally well, making it a practical alternative for resource-limited settings and self-directed monitoring.	The DAS28 is a composite measure of rheumatoid arthritis (RA) disease activity, combining joint counts, inflammatory markers, and patient-reported global health. Developed in 1995 by Prevoo and colleagues, it has become the gold standard for monitoring RA activity in clinical trials and practice. It integrates objective clinical signs with laboratory and subjective assessment, providing a single numerical index of disease burden.	The SLEDAI is a comprehensive clinician-assessed measure of systemic lupus erythematosus (SLE) disease activity, capturing manifestations across multiple organ systems (cutaneous, renal, neuropsychiatric, hematologic, and serological). Introduced by Bombardier et al. (1992) and refined as SLEDAI-2K by Gladman et al. (2002), SLEDAI uses weighted scoring of 24 clinical and laboratory features to quantify overall SLE activity. It is the most widely used outcome measure in SLE research and clinical trials, enabling standardised assessment of disease progression, flare prediction, and treatment response in this complex multisystem disease.